NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.809
+0.058 (7.78%)
At close: Apr 28, 2026, 4:00 PM EDT
0.791
-0.018 (-2.23%)
After-hours: Apr 28, 2026, 6:19 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
28.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Jasper Therapeutics | 22 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
| Lantern Pharma | 16 |
| Barinthus Biotherapeutics | 14 |
| Apollomics | 13 |
| AEON Biopharma | 8 |
NRSN News
- 12 hours ago - NeuroSense Announces Pricing of Insider-Led PIPE Financing - PRNewsWire
- 22 days ago - NeuroSense Granted Brazilian Patent Covering PrimeC Composition - PRNewsWire
- 25 days ago - NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - PRNewsWire
- 5 weeks ago - PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PRNewsWire
- 6 weeks ago - JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PRNewsWire
- 7 weeks ago - PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PRNewsWire